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Non-alcoholic fatty liver disease (NAFLD)
encompasses the often benign non-alcoholic fatty liver
(NAFL) characterized by hepatic steatosis with or
without mild inflammation and the more complicated
non-alcoholic steatohepatitis (NASH) with lobular
inflammation and hepatocellular ballooning which can
be complicated by fibrosis.1 Independent associates for
the presence of liver fibrosis in patients with NASH are
diabetes mellitus (DM), insulin resistance, hypertension,
weight gain, and increased serum alanine and aspartate
aminotransferase.2 NAFLD patients with fibrosis are at
increased risk for liver cirrhosis. The estimated risks to
develop liver cirrhosis are for patients with NASH and
patients with NAFL, 22% and 4%, respectively.3
In the last decade, the prevalence of NAFLD has
tremendously increased as a result of the world-wide raise
of patients with DM and obesity (i.e., metabolic syn-
drome). This has led to a fivefold increase of NAFLD-
related liver transplantation.4 Moreover, NAFLD is con-
sidered to be the hepatic expression of the metabolic
syndrome5 with augmented atherogenesis expressed by
increased carotid intima-media thickness (CIMT),
endothelial dysfunction, arterial stiffness, impaired left
ventricular function, and coronary calcification. As a
result, patients with NAFLD have an increased risk for
cardiovascular (CV) disease and mortality.6-8
Among others, Adams et al demonstrated that the 10-
year survival of patients with NAFLD was significantly
lower compared with the general population (77 vs 87%,
P[log-rank] = 0.005), due to higher frequency of fatal CV
disease and malignancy.8 In addition, Targher et al
demonstrated that the presence ofNAFLD in asymptomatic
patients with DM type 2 was independently associated with
an increased risk for myocardial infarction, coronary
revascularization procedures, ischemic stroke, and/or CV
death (odds ratio 1.84, 95% CI 1.4;2.1, P\0.001).6
Currently, the diagnostic reference standard to
diagnose NAFLD is a liver biopsy.9 However, in an
asymptomatic population this invasive technique is not
practical as a screening method and not without hazards.
Therefore, as an alternative technique, positron emission
tomography (PET)/computed tomography (CT) can be
used to detect hepatic inflammation by means of the
glucose tracer fluorine-18 fluoro-2-deoxyglucose (18F-
FDG). 18F-FDG visualizes the importance and utiliza-
tion of glucose (metabolic activity) of the cells and is
expected to be higher in inflammatory cells.10 The major
drawback of this method is that 18F-FDG PET/CT
cannot differentiate between hepatic histologic subtypes.
Results of studies evaluating the hepatic uptake of
18F-FDG measured with PET or PET/CT in NAFLD
patients are controversial.11-13 Abikhzer et al demon-
strated in patients with hepatic steatosis a small global
decrease in hepatic metabolic activity corrected for lean
body mass in comparison with controls.12 However,
there was no difference when the hepatic standard
uptake value (SUV) of 18F-FDG was corrected for body
weight. In addition, Lin et al demonstrated a signifi-
cantly negative correlation in the degree of fatty liver
and the maximum hepatic SUV of 18F-FDG on PET.11
In contrast, Bural et al showed higher maximum hepatic
SUVs on PET in subjects with diffuse hepatic steatosis
compared to those in the control group.13 A part of the
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differences in results of the hepatic SUV of 18F-FDG in
patients with NAFLD can be explained by the fact that
some studies did not take into account lean body mass,
glucose levels, and 18F-FDG dose.
Recently, Hong et al demonstrated in 331 asymp-
tomatic men with NAFLD a significantly increased
mean hepatic 18F-FDG SUV of 2.40 ± 0.25 in com-
parison with a mean hepatic 18F-FDG SUV of
2.28 ± 0.26 in 349 controls. In addition, the increased
uptake was closely correlated with serum c-glutamyl
transpeptidase and triglycerides, markers for hepatic
inflammation and injury.14
In this issue of the journal, the same group
addressed the role of hepatic 18F-FDG uptake for pre-
dicting future CV and cardio-cerebrovascular events and
evaluated its prognostic value in comparison with other
CV risk factors including the Framingham risk score and
CIMT.15 In a recent study, 815 asymptomatic partici-
pants underwent a health screening program that
consisted of 18F-FDG PET/CT, abdominal ultrasonog-
raphy, and CIMT measurements. The primary endpoint
consisted of CV events including myocardial infarction,
coronary intervention for significant coronary stenosis,
and angina requiring an emergency room visit with
demonstration of significant coronary stenosis. Addi-
tional analysis evaluated the combined endpoint
cerebrovascular (consisting of stroke, transient ischemic
attacks, and deaths) and cardiovascular events. Moon
et al demonstrated that the only independent factor for
future CV events in this asymptomatic population was
the combination of high hepatic FDG uptake and
NAFLD (determined by abdominal sonography and
questionnaire about alcohol intake). This remained after
including cerebrovascular events. In the NAFLD sub-
group, high hepatic FDG uptake and male were
independently associated with future CV events. For the
combined endpoint cardio-cerebrovascular events, only
high hepatic FDG uptake was an independent factor in
the NAFLD subgroup. However, the conclusions of the
authors should be placed in a broader perspective. First,
the study results might not be representative for the
general population since the study population comprised
a high percentage of male ([90%). Second, there were
some small differences in the procedure of patients’
preparation for 18F-FDG PET/CT in comparison with
the guidelines which might influence the implementa-
tion.16 The cut-off value of blood glucose levels at the
time of FDG injection was higher (\200 mg/dl instead
of an upper plasma level range between 126 and
150 mg/dl which is nowadays recommended in a
research population). Third, evaluation of CV and car-
dio-cerebrovascular events in an asymptomatic cohort is
challenging since event rates are low. In line with
expected, the CV event rates were indeed low, in the
control group as well as in the NAFLD group, 0.7% (3/
421) and 1.5% (6/394), respectively. Therefore, con-
clusions on differences in CV event rates between
patients with and without NAFLD are based on an
absolute difference of 3 events. In the additional analysis
after inclusion of cerebrovascular events, the absolute
difference in events between the groups was even
smaller, only 2 events (1.2% (5/421) vs 1.8% (7/394),
respectively). Although independently associated in
multivariate analyses, the additive value of screening
asymptomatic patients for NAFLD in combination with
increased hepatic 18F-FDG SUV on PET/CT on top of
traditional risk scores is limited given the small absolute
numbers. As well, the radiation exposure of PET/CT
should be taken into account. The effective dose from
18F-FDG in adults is about 7 mSv for an administrated
activity of 370 MBq.17 On top, the CT-related radiation
dose should be added. This radiation dose differs from
patient to patient and ranges from 1 up to 20 mSv,
depending on the type of scanner and body mass index.
In conclusion, we have to be aware that patients with
NAFLD and no cardio-cerebrovascular complaints are at
increased risk for these events. However, since we
realize that a liver biopsy is not the ideal screening tool,
determining hepatic FDG uptake on PET/CT scan could
be a good non-invasive alternative to estimate the risk of
these patients but needs more data and convincing proof.
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